The clinical value of tau PET in the memory clinic (TAP-TAU)

Conditions

Mild cognitive impairment and dementia

Brief summary

Pre- vs. post-tau PET change in diagnosis (diagnostic categories: AD, non-AD with specification of suspected underlying pathology, mixed AD/non-AD pathology) and comparison with a control group after a year, Pre- vs. post-tau PET change in confidence of the clinician in the etiological diagnosis (continuous scale ranging from 0-100%, baseline <85% required) and comparison with a control group after a year., Pre- vs. post-tau PET change in patient management (increase or reduction in ancillary investigations, initiation or withdrawal of medication, initiation or withdrawal of care; we will also assess whether it would influence hypothetical prescription of disease modifying treatment of AD) and comparison with a control group after a year., Pre- vs. post-tau PET change in patient wellbeing (measures of anxiety and uncertainty) and behavioural intentions and post-tau PET perceptions, experiences and understanding of tau PET.

Detailed description

Performance of tau PET compared to novel blood-based biomarkers and artificial intelligence (AI) based classifiers.

Marie R. Vermeiren, Joost F. Somsen, Gert Luurtsema, Fransje E. Reesink, Nicolaas A. Verwey et al. (20 authors)

Alzheimer s Research & Therapy2024-10-194 citations

10.1186/s13195-024-01588-4

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGFlortaucipir

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Pre- vs. post-tau PET change in diagnosis (diagnostic categories: AD, non-AD with specification of suspected underlying pathology, mixed AD/non-AD pathology) and comparison with a control group after a year, Pre- vs. post-tau PET change in confidence of the clinician in the etiological diagnosis (continuous scale ranging from 0-100%, baseline <85% required) and comparison with a control group after a year., Pre- vs. post-tau PET change in patient management (increase or reduction in ancillary investigations, initiation or withdrawal of medication, initiation or withdrawal of care; we will also assess whether it would influence hypothetical prescription of disease modifying treatment of AD) and comparison with a control group after a year., Pre- vs. post-tau PET change in patient wellbeing (measures of anxiety and uncertainty) and behavioural intentions and post-tau PET perceptions, experiences and understanding of tau PET.	—

Measure

Time frame

Pre- vs. post-tau PET change in diagnosis (diagnostic categories: AD, non-AD with specification of suspected underlying pathology, mixed AD/non-AD pathology) and comparison with a control group after a year, Pre- vs. post-tau PET change in confidence of the clinician in the etiological diagnosis (continuous scale ranging from 0-100%, baseline <85% required) and comparison with a control group after a year., Pre- vs. post-tau PET change in patient management (increase or reduction in ancillary investigations, initiation or withdrawal of medication, initiation or withdrawal of care; we will also assess whether it would influence hypothetical prescription of disease modifying treatment of AD) and comparison with a control group after a year., Pre- vs. post-tau PET change in patient wellbeing (measures of anxiety and uncertainty) and behavioural intentions and post-tau PET perceptions, experiences and understanding of tau PET.

—

Secondary

Measure	Time frame
Performance of tau PET compared to novel blood-based biomarkers and artificial intelligence (AI) based classifiers.	—

Countries

Netherlands

Outcome results

None listed